| Peer-Reviewed

Investigation and Analysis of the Information Available for Pregnant and Lactating Women in 308 Antipsychotic Package Inserts

Received: 8 June 2021     Accepted: 18 June 2021     Published: 25 June 2021
Views:       Downloads:
Abstract

Background: Package insert is an important tool to provide safe and reasonable guidance for pregnant and lactating women. Methods: The information on pregnant women in 308 package inserts of 38 kinds of antipsychotics on the market was analyzed. Results: 287 (93.18%) package inserts in the 308 antipsychotics provide drug use guiding information for pregnant women, while 150 (48.70%) of them made it clear that the drug could be used normally, cautiously or forbidden on pregnant women. 137 (44.48%) of them used different expressions. There were 64 (20.78%) instructions that made it clear that the drug could be used normally, cautiously or forbidden on lactation women. 81 (26.30%) instructions are recommended to stop breastfeeding. 142 (46.10%) instructions for breastfeeding women used different expressions. Contradictions were found in 23.53% drugs for pregnant women and 29.41% for lactation women. Conclusion: There are some problems with drug information on pregnant women in package inserts,such as inadequate information and inaccurate description. To ensure safer use, the package inserts of medicines should be further improved.

Published in Journal of Gynecology and Obstetrics (Volume 9, Issue 3)
DOI 10.11648/j.jgo.20210903.15
Page(s) 79-83
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Package Inserts, Antipsychotics, Pregnant Women, Lactating Women

References
[1] Wang QM. Investigation and analysis of medication labeling for pregnant and lactating women in 616 drug product inserts [J]. Journal of Practical Medical Techniques, 2016, 23: 667.
[2] Einarson A. Boskovic R. Use and safety of antipsychotic drugs during pregnancy [J]. Journal of Psychiatric Practice, 2019, 15 (3): 183-192.
[3] Zhai Q. Zhang GF. Liu M. et al. Rational application of antipsychotics in pregnanc [J]. Chinese General Practice, 2019, 22 (30): 3701-3708.
[4] Huang JW. Li JF. Zhang ZD. et al. Analysis of Drug Information on Pregnant Women in 247 Package Inserts of Antiviral Drugs [J]. Pharmacy Today, 2016, 26 (7): 522-524.
[5] Feng N. (2017). Investigation and Analysis of Medication Information on Pregnant Women in 166 Drug Instructions of Anti-diabetic Drugs [J]. China Pharmacy, 2017, 28 (16): 2301-2304.
[6] Niu JR. Li J. Wu S. et a. Analysis of drug use labeling for pregnant and lactating women in 762 drug package inserts [J]. China Pharmacy, 27 (7): 992-994.
[7] Liu YQ. Wang ZJ. Liang YQ. Analysis on the Publication of Revision Notices of Drug Instructions and Related Status in China in 2015-2019 [J]. China Pharmacy, 2019, 30 (21): 2903-2908.
[8] Margulis AV. Kang EM, Hammad TA. Patterns of prescription of antidepressants and antipsychotics across and within pregnancies in a population-based UK cohor [J]. Matern Child Health J. 2014, 18 (7): 1742-1752.
[9] Sabahi A. Sepehri G. Mohsenbeigi M. et al. Patterns of psychotropic medication prescriptions by psychiatrists for private clinic outpatients in kerman province, iran [J]. Sultan Qaboos University Medical Journal. 2014, 14 (3): e382-387.
[10] Hanley GE. Oberlander TF. The effect of perinatal exposures on the infant: antidepressants and depression [J]. Best practice & research Clinical obstetrics & gynaecology, 2014, 28 (1): 37-48.
[11] Muzik M. & Hamilton SE. Use of antidepressants during pregnancy: what to consider when weighing treatment with antidepressants against untreated depression [J]. Maternal & Child Health Journal, 2016, 20 (11): 1-12.
[12] Weisskopf E. Fischer CJ. Bickle Graz M. et al. Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence [J]. Expert opinion on drug safety, 2015, 14 (3): 413-427.
[13] Zhang YY. Li SX. Li ZH. Research progress on the safety of exposure to selective serotonin reuptake inhibitors during pregnancy [J]. Adverse Drug Reactions Journal, 2021, 23 (3): 140-144.
[14] Bérard A. Zhao JP. Sheehy O. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the quebec pregnancy cohort [J]. Bmj Open, 2017, 7 (1): e013372.
[15] Yu DS. Effects of antidepressants on pregnancy and lactation [J]. Journal of Clinical Psychiatry, 2012, 22 (1): 60-62.
Cite This Article
  • APA Style

    Xiaoru Yang, Jufeng Li, Jieyi Zhou, Xiaofei Feng, Jiawen Huang. (2021). Investigation and Analysis of the Information Available for Pregnant and Lactating Women in 308 Antipsychotic Package Inserts. Journal of Gynecology and Obstetrics, 9(3), 79-83. https://doi.org/10.11648/j.jgo.20210903.15

    Copy | Download

    ACS Style

    Xiaoru Yang; Jufeng Li; Jieyi Zhou; Xiaofei Feng; Jiawen Huang. Investigation and Analysis of the Information Available for Pregnant and Lactating Women in 308 Antipsychotic Package Inserts. J. Gynecol. Obstet. 2021, 9(3), 79-83. doi: 10.11648/j.jgo.20210903.15

    Copy | Download

    AMA Style

    Xiaoru Yang, Jufeng Li, Jieyi Zhou, Xiaofei Feng, Jiawen Huang. Investigation and Analysis of the Information Available for Pregnant and Lactating Women in 308 Antipsychotic Package Inserts. J Gynecol Obstet. 2021;9(3):79-83. doi: 10.11648/j.jgo.20210903.15

    Copy | Download

  • @article{10.11648/j.jgo.20210903.15,
      author = {Xiaoru Yang and Jufeng Li and Jieyi Zhou and Xiaofei Feng and Jiawen Huang},
      title = {Investigation and Analysis of the Information Available for Pregnant and Lactating Women in 308 Antipsychotic Package Inserts},
      journal = {Journal of Gynecology and Obstetrics},
      volume = {9},
      number = {3},
      pages = {79-83},
      doi = {10.11648/j.jgo.20210903.15},
      url = {https://doi.org/10.11648/j.jgo.20210903.15},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jgo.20210903.15},
      abstract = {Background: Package insert is an important tool to provide safe and reasonable guidance for pregnant and lactating women. Methods: The information on pregnant women in 308 package inserts of 38 kinds of antipsychotics on the market was analyzed. Results: 287 (93.18%) package inserts in the 308 antipsychotics provide drug use guiding information for pregnant women, while 150 (48.70%) of them made it clear that the drug could be used normally, cautiously or forbidden on pregnant women. 137 (44.48%) of them used different expressions. There were 64 (20.78%) instructions that made it clear that the drug could be used normally, cautiously or forbidden on lactation women. 81 (26.30%) instructions are recommended to stop breastfeeding. 142 (46.10%) instructions for breastfeeding women used different expressions. Contradictions were found in 23.53% drugs for pregnant women and 29.41% for lactation women. Conclusion: There are some problems with drug information on pregnant women in package inserts,such as inadequate information and inaccurate description. To ensure safer use, the package inserts of medicines should be further improved.},
     year = {2021}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Investigation and Analysis of the Information Available for Pregnant and Lactating Women in 308 Antipsychotic Package Inserts
    AU  - Xiaoru Yang
    AU  - Jufeng Li
    AU  - Jieyi Zhou
    AU  - Xiaofei Feng
    AU  - Jiawen Huang
    Y1  - 2021/06/25
    PY  - 2021
    N1  - https://doi.org/10.11648/j.jgo.20210903.15
    DO  - 10.11648/j.jgo.20210903.15
    T2  - Journal of Gynecology and Obstetrics
    JF  - Journal of Gynecology and Obstetrics
    JO  - Journal of Gynecology and Obstetrics
    SP  - 79
    EP  - 83
    PB  - Science Publishing Group
    SN  - 2376-7820
    UR  - https://doi.org/10.11648/j.jgo.20210903.15
    AB  - Background: Package insert is an important tool to provide safe and reasonable guidance for pregnant and lactating women. Methods: The information on pregnant women in 308 package inserts of 38 kinds of antipsychotics on the market was analyzed. Results: 287 (93.18%) package inserts in the 308 antipsychotics provide drug use guiding information for pregnant women, while 150 (48.70%) of them made it clear that the drug could be used normally, cautiously or forbidden on pregnant women. 137 (44.48%) of them used different expressions. There were 64 (20.78%) instructions that made it clear that the drug could be used normally, cautiously or forbidden on lactation women. 81 (26.30%) instructions are recommended to stop breastfeeding. 142 (46.10%) instructions for breastfeeding women used different expressions. Contradictions were found in 23.53% drugs for pregnant women and 29.41% for lactation women. Conclusion: There are some problems with drug information on pregnant women in package inserts,such as inadequate information and inaccurate description. To ensure safer use, the package inserts of medicines should be further improved.
    VL  - 9
    IS  - 3
    ER  - 

    Copy | Download

Author Information
  • Department of Pharmacy, First Affiliated Hospital, Jinan University, Guangzhou, China

  • Department of Pharmacy, First Affiliated Hospital, Jinan University, Guangzhou, China

  • Department of Pharmacy, First Affiliated Hospital, Jinan University, Guangzhou, China

  • Department of Pharmacy, First Affiliated Hospital, Jinan University, Guangzhou, China

  • Department of Pharmacy, First Affiliated Hospital, Jinan University, Guangzhou, China

  • Sections